Travere Therapeutics
Develops and sells rare kidney-disease medicines led by FILSPARI.
$65.49
After-hours close−0.16 (−0.24%)
At close$65.65(−2.77%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 119.79%Insiders 1.61%
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 92.99M · Float 90.37M · 97.2% free float
Institutions13F, as of Jun 30, 2026
330 holders · 111.40M shares · 89 new positions · 211 increased · 85 reduced · 33 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Jupiter Topco LLC | 11.32M | 12.18% | +11.32Mnew | Aug 14, 2026 |
| BlackRock, Inc. | 8.02M | 8.63% | +228.6K | Aug 7, 2026 |
| FMR LLC | 7.10M | 7.63% | −3.87M | Aug 13, 2026 |
| Bank of America Corp /DE/ | 4.57M | 4.91% | +3.22M | Aug 14, 2026 |
| State Street Corp | 4.26M | 4.58% | −703.8K | Aug 7, 2026 |
| Vanguard Capital Management LLC | 4.11M | 4.42% | +62.9K | Aug 13, 2026 |
| Perceptive Advisors LLC | 3.75M | 4.04% | −390.0K | Aug 14, 2026 |
| Macquarie Management Holdings, Inc. | 2.81M | 3.02% | −458.0K | Aug 14, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Janus Henderson Group PLC | 11.90% | 10.60M | 13G | Nov 14, 2025 ↗ |
| FMR LLC | 11.70% | 10.57M | 13G | Jan 8, 2026 ↗ |
| Armistice Capital, LLC | 9.96% | 8.88M | 13G | Aug 15, 2025 ↗ |
| BlackRock, Inc. | 7.50% | 6.69M | 13G | Apr 17, 2025 ↗ |
| Woodline Partners LP | 5.70% | 4.34M | 13G | Nov 14, 2024 ↗ |
| Vanguard Capital Management | 5.09% | 4.70M | 13G | Apr 30, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Eric M. Dube | director, officer: CHIEF EXECUTIVE OFFICER | 432.9K | 0.47% | May 6, 2026 |
| Peter Heerma | officer: CHIEF COMMERCIAL OFFICER | 140.7K | 0.15% | May 6, 2026 |
| Christopher R. Cline | officer: CHIEF FINANCIAL OFFICER | 118.7K | 0.13% | May 6, 2026 |
| William E. Rote | officer: Chief Research Officer | 115.5K | 0.12% | May 6, 2026 |
| Jula Inrig | officer: CHIEF MEDICAL OFFICER | 112.8K | 0.12% | Jun 22, 2026 |
| Elizabeth E. Reed | officer: Chief Legal Officer and GC | 105.2K | 0.11% | May 6, 2026 |
| Jeffrey A. Meckler | director | 91.5K | 0.10% | May 21, 2026 |
| Gary A. Lyons | director | 61.5K | 0.07% | Aug 19, 2026 |
| Timothy Coughlin | director | 56.3K | 0.06% | Jun 16, 2026 |
| Sandra Calvin | officer: SVP, CHIEF ACCOUNTING OFFICER | 42.4K | 0.05% | Apr 16, 2026 |
3 ten-percent owners hold 6.52M shares by Form 4, outside the officers-and-directors figure above · 12 people have not refiled in the last 18 months (1.04M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 18, 2026 | Gary A. Lyonsdirector | Sale · 2 lots | 5,000 | $63.37 | 61,500 |
| Aug 17, 2026 | Gary A. Lyonsdirector | Sale · 3 lots | 5,000 | $63.20 | 61,500 |
| Jun 12, 2026 | Roy D. Baynesdirector | Sale | 4,500 | $50.00 | 41,500 |
| Jun 12, 2026 | Timothy Coughlindirector | Sale | 10,000 | $50.07 | 56,250 |
| May 15, 2026 | Timothy Coughlindirector | Sale | 3,250 | $43.49 | 52,250 |
| May 6, 2026 | Christopher R. Clineofficer: CHIEF FINANCIAL OFFICER | Sale | 310 | $43.95 | 118,658 |
| May 5, 2026 | Christopher R. Clineofficer: CHIEF FINANCIAL OFFICER | Sale | 2,181 | $46.65 | 118,968 |
| May 6, 2026 | Eric M. Dubedirector, officer: CHIEF EXECUTIVE OFFICER | Sale | 22,500 | $43.95 | 432,886 |
| May 5, 2026 | Peter Heermaofficer: CHIEF COMMERCIAL OFFICER | Sale | 2,174 | $46.65 | 140,684 |
| May 4, 2026 | Jula Inrigofficer: CHIEF MEDICAL OFFICER | Sale | 20,000 | $45.00 | 111,473 |
CongressHouse and Senate disclosures
Not reported.